# Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

> **NCT00353288** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 446 (actual)

## Conditions studied

- Varicella
- Rubella
- Measles
- Mumps

## Interventions

- **BIOLOGICAL:** MeMuRu-OKA (study vacc)
- **BIOLOGICAL:** MMR, Varicella vacc (control)

## Key facts

- **NCT ID:** NCT00353288
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2016-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353288, "Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00353288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*